Archives: Projects/Publication

Efficacy and safety of Intravitreal Aflibercept Vs Verteporfin Photodynamic Therapy in a Caucasian Population with Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial

Efficacy and safety of Intravitreal Aflibercept Vs Verteporfin Photodynamic Therapy in a Caucasian Population with Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial

Rufino Silva, Luis Arias, Sandrina Nunes, Claudia Farinha, Rita Coimbra, João P Maques, Maria L Cachulo, João Figueira, Patricia Barreto, Maria H Madeira, Isabel Pires, João C Sousa, Laura Distefano, Paulo Rosa, Ângela Carneiro, Sara Vaz-Pereira, Angelina Meireles, Francisco Cabrera, Anniken Bures, Luís Mendonça, Alvaro Fernandez-Vega Sanz, Sandra Barrão, Adrian Koh, Chui Ming Gemmy Cheung, José G Cunha-Vaz, Joaquim Murta, EVICR.net ATLANTIC Study Group

Ophthalmologica . 2021 Jul 13. doi: 10.1159/000518235.

2021

https://www.karger.com/Article/Abstract/518235

Challenges, facilitators and barriers to screening study participants in early disease stages-experience from the MACUSTAR study

Challenges, facilitators and barriers to screening study participants in early disease stages-experience from the MACUSTAR study

Terheyden JH, Behning C, Lüning A, Wintergerst L, Basile PG, Tavares D, Melício BA, Leal S, Weissgerber G, Luhmann UFO, Crabb DP,Tufail A, Hoyng CB, Berger M, Schmid M, Silva R , Martinho CV, Cunha-Vaz J, Holz FG, Finger RP, MACUSTAR consortium

BMC Med Res Methodol. 2021 Mar 17;21(1):54. doi: 10.1186/s12874-021-01243-8.

2021

Current management of patients with RPE65 mutation-associated inherited retinal degenerations (IRDs) in Europe. Results of a multinational survey by the European Vision Institute Clinical Research Network EVICR.net

Current management of patients with RPE65 mutation-associated inherited retinal degenerations (IRDs) in Europe. Results of a multinational survey by the European Vision Institute Clinical Research Network EVICR.net

Lorenz B, Tavares J, van den Born LI, Marques JP, Scholl HPN, The EVICR.net Group

2021 Mar 8. doi: 10.1159/00051568

2021

Real-world intensive safety monitoring of biosimilars rituximab and trastuzumab in a Portuguese oncology hospital

Real-world intensive safety monitoring of biosimilars rituximab and trastuzumab in a Portuguese oncology hospital

Mendes D, Abrantes J, Rigueiro G, Pais AF, Penedones A, Alves C, Batel Marques F.

J Oncol Pharm Pract. 2020 Sep 16;1078155220957079. doi: 10.1177/1078155220957079.

2020

https://journals.sagepub.com/doi/10.1177/1078155220957079?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Emerging Trends in Nanomedicine for Improving Ocular Drug Delivery: Light-Responsive Nanoparticles, Mesoporous Silica Nanoparticles, and Contact Lenses

Emerging Trends in Nanomedicine for Improving Ocular Drug Delivery: Light-Responsive Nanoparticles, Mesoporous Silica Nanoparticles, and Contact Lenses

Rodrigues F, Campos A, Martins J. Ambrosio AF, Campos EJ.

ACS Biomater. Sci. Eng. 2020 https://doi.org/10.1021/acsbiomaterials.0c01347.

2020

https://pubs.acs.org/doi/pdf/10.1021/acsbiomaterials.0c01347

Swept source OCTA quantification of capillary closure predicts ETDRS severity staging of NPDR

Swept source OCTA quantification of capillary closure predicts ETDRS severity staging of NPDR

Santos T, Lewis W, Santos AR, Marques IP, Kubach S, Mendes L, Sisternes L, Madeira MH, Durbin MK, Cunha-Vaz J.

British Journal of Opthalmology2020 Dec 22:bjophthalmol-2020-317890. doi: 10.1136/bjophthalmol-2020-317890.

2020

https://bjo.bmj.com/content/bjophthalmol/early/2020/12/22/bjophthalmol-2020-317890.full.pdf

Ocular and systemic risk markers for development of Macular Edema and Proliferative Retinopathy in type 2 diabetes. A five-year longitudinal study

Ocular and systemic risk markers for development of Macular Edema and Proliferative Retinopathy in type 2 diabetes. A five-year longitudinal study

Martinho AC-V, Marques IP, Messias AL, Santos T, Madeira MH, Sousa DC, Cunha-Vaz J.

Diabetes Care. 2021 Jan;44(1):e12-e14. doi: 10.2337/dc20-1125

2021

https://care.diabetesjournals.org/content/44/1/e12.long

Development of a Genotype Assay for Age-Related Macular Degeneration: The EYE-RISK Consortium

Development of a Genotype Assay for Age-Related Macular Degeneration: The EYE-RISK Consortium

de Breuk A, Acar IE, Kersten E, Schijvenaars MMVAP, Colijn JM, Haer-Wigman L, Bakker B, de Jong S, Meester-Smoor MA, Timo Verzijden, Missotten TOAR, Monés J, Biarnés M, Pauleikhoff D, Hense HW, Silva R, Nunes S, Melo JB, Fauser S, Hoyng CB, Ueffing M, Coenen MJH, Klaver CCW, den Hollander AI, EYE-RISK Consortium.

Ophthalmology. 2020 Jul 24;S0161-6420(20)30725-9. doi: 10.1016/j.ophtha.2020.07.037.

https://reader.elsevier.com/reader/sd/pii/S0161642020307259?token=7C3855F4931D40A7D8232C4B1BE25B807B16462FA80BF01A4237E6905759EF9DBBC9F32B3AB5F0B94D301274E08CA61C

Use of composite endpoints in early and intermediate age-related macular degeneration clinical trials – state-of-the-art and future directions

Use of composite endpoints in early and intermediate age-related macular degeneration clinical trials – state-of-the-art and future directions

Terheyden J.H. Schmitz-Valckenberg S. Crabb D. Dunbar H. Luhmann U. Behning C. Schmid M. Pires I. Cunha-Vaz J. Tufail A. Weissgerber G. Leal S. Holz F.G. Finger R.P.

Ophthalmologica. 2020 Dec 7. doi: 10.1159/000513591.

https://www.karger.com/Article/Abstract/513591

Microglia Dysfunction Caused by the Loss of Rhoa Disrupts Neuronal Physiology and Leads to Neurodegeneration

Microglia Dysfunction Caused by the Loss of Rhoa Disrupts Neuronal Physiology and Leads to Neurodegeneration.

Renato Socodato, Camila C.Portugal, Teresa Canedo, Artur Rodrigues, Tiago O.Almeida, Joana F.Henriques, Sandra H.Vaz, João Magalhães, Cátia M.Silva, Filipa I.Baptista, Renata L.Alves Vanessa Coelho-Santos, Ana Paula Silva, Roberto Paes-de-Carvalho, Ana Magalhães, Cord Brakebusch, Ana M.Sebastião, Teresa Summavielle, A. Francisco Ambrosio, João B.Relvas

Cell reports, Volume 31, Issue 12, 23 June 2020, 107796

2020